了解偏头痛治疗的有效性和耐受性:深入研究CGRP对手
Marta Waliszewska-Prosół1, Bianca Raffaelli2,3, Marcin Straburzyński4
1Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Expert review of clinical pharmacology
|October 16, 2024
概括
素基因相关 (CGRP) 向治疗为偏头痛患者提供了新的希望,比传统治疗方法更有效. 需要进一步的研究来优化它们在头痛医学中的使用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 素基因相关 (CGRP) 在偏头痛的发病过程中起着至关重要的作用.
- 这种理解推动了新型偏头痛治疗的发展.
研究的目的:
- 审查CGRP在偏头痛中的作用.
- 讨论CGRP向治疗的疗效.
- 探索关于CGRP对手应用的剩余问题.
主要方法:
- 关于CGRP在偏头痛中的作用的文献综述.
- 对CGRP向疗法的临床试验数据的分析.
- 关于当前和未来应用的专家意见.
主要成果:
- 与传统偏头痛治疗相比,CGRP向药物显示出更高的疗效和耐受性.
- 这些疗法为那些对传统护理反应不足的患者提供了显著的希望.
结论:
- CGRP对抗剂代表了偏头痛治疗的变革性进展.
- 需要进一步的观察和研究来完善它们的实际应用.
- 普遍获得CGRP向疗法对于管理慢性偏头痛和药物过量使用头痛至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
151
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
151
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
179
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
179
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
218
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
218
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462
Cholinergic Antagonists: Therapeutic Uses
724
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
724
Drugs Acting on Autonomic Ganglia: Blockers
970
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
970


